Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.
Authors: Reiss KA; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia., Xia M; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia., Akamandisa M; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia.; Department of Genetics, Yale University, New Haven, Connecticut., D'Andrea K; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia., Wubbenhorst B; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia., Lord CJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Pettitt SJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Tutt ANJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK., Brown TJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Hematology/Oncology, University of Texas Southwestern, Dallas., O'Hara MH; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia., Schneider C; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia., Teitelbaum U; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia., Hannan Z; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia.; Internal Medicine Residency Program, Main Line Health System, Philadelphia, Pennsylvania., Hood R; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia.; Miller School of Medicine, University of Miami, Miami, Florida., Tondon R; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia., Vonderheide RH; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia., Domchek SM; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Medical Oncology, University of Pennsylvania, Philadelphia.; The Basser Center for BRCA, University of Pennsylvania, Philadelphia., Nathanson KL; Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Department of Medicine, Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia.; The Basser Center for BRCA, University of Pennsylvania, Philadelphia.
Source: JAMA oncology [JAMA Oncol] 2026 Jun 01; Vol. 12 (6), pp. 666-670.
Publication Type: Journal Article
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2374-2445
DOI:10.1001/jamaoncol.2026.0870